ES2093445T3 - Inyeccion y estuche de inyeccion que contiene omeprazol y sus analogos. - Google Patents

Inyeccion y estuche de inyeccion que contiene omeprazol y sus analogos.

Info

Publication number
ES2093445T3
ES2093445T3 ES93916182T ES93916182T ES2093445T3 ES 2093445 T3 ES2093445 T3 ES 2093445T3 ES 93916182 T ES93916182 T ES 93916182T ES 93916182 T ES93916182 T ES 93916182T ES 2093445 T3 ES2093445 T3 ES 2093445T3
Authority
ES
Spain
Prior art keywords
injection
pct
analogs
case containing
containing omeprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916182T
Other languages
English (en)
Inventor
Shigeo Nakanishi
Tetsuo Tominaga
Iwao Yamanaka
Takashi Higo
Toshiyuki Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16437061&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2093445(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of ES2093445T3 publication Critical patent/ES2093445T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

UNA INYECCION QUE CONTIENE UN COMPUESTO DE 2-[(2PIRIDIL)METILSULFINIL]-BENCIMIDAZOL O UNA SAL DEL MISMO QUE TIENEN UNA ACTIVIDAD ANTIULCERAS Y UN SOLVENTE ACUOSO AL QUE SE AÑADE UN SOLVENTE NO ACUOSO, EN DONDE EL PH DE LA INYECCION NO ES INFERIOR A 9,5 Y NO ES SUPERIOR A 11,5 Y UN KIT DE INYECCION QUE CONTIENE LAS SIGUIENTES (A) Y (B), EN DONDE (A) Y (B) SE AJUSTAN DE TAL MODO QUE EL PH TRAS LA DISOLUCION DE (A) EN (B) SEA DE 9,5 A 11,5: (A): UN PRODUCTO LIOFILIZADO DE UNA SOLUCION ACUOSA ALCALINA DE UN COMPUESTO DE 2-[(2-PIRIDIL)METILSULFINIL]BENCIMIDAZOL O UNA SAL DEL MISMO QUE TIENEN UNA ACTIVIDAD ANTIULCERAS; (B): UN SOLVENTE ACUOSO AL QUE SE AÑADE UN SOLVENTE NO ACUOSO. CON LA INYECCION DE LA PRESENTE INVENCION NO ES NECESARIO REDUCIR EL PH PARA PREVENIR LA HEMOLISIS O IRRITACION LOCAL, NI AÑADIR UN SOLVENTE NO ACUOSO A UN SOLVENTE ACUOSO PARA LA DISOLUCION PARA PREVENIR LA DEGRADACION CONCOMITANTE DE LAS PROPIEDAD DE DISOLUCION. SEGUN ESTO, LA INYECCION DE LA PRESENTE INVENCION PUEDEASEGURAR UNA SOLUBILIDAD SUFICIENTE PARA LA FORMULACION DE UNA PREPARACION Y SEGURIDAD PARA EL CUERPO HUMANO.
ES93916182T 1992-07-28 1993-07-15 Inyeccion y estuche de inyeccion que contiene omeprazol y sus analogos. Expired - Lifetime ES2093445T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20120392 1992-07-28

Publications (1)

Publication Number Publication Date
ES2093445T3 true ES2093445T3 (es) 1996-12-16

Family

ID=16437061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916182T Expired - Lifetime ES2093445T3 (es) 1992-07-28 1993-07-15 Inyeccion y estuche de inyeccion que contiene omeprazol y sus analogos.

Country Status (20)

Country Link
US (1) US5589491A (es)
EP (1) EP0652751B1 (es)
KR (1) KR100258423B1 (es)
AT (1) ATE144421T1 (es)
AU (1) AU674015B2 (es)
CA (1) CA2140347C (es)
CZ (1) CZ284249B6 (es)
DE (1) DE69305642T2 (es)
DK (1) DK0652751T3 (es)
ES (1) ES2093445T3 (es)
FI (1) FI113338B (es)
GR (1) GR3021937T3 (es)
HK (1) HK52397A (es)
HU (1) HU226778B1 (es)
NO (1) NO304098B1 (es)
NZ (1) NZ254237A (es)
RU (1) RU2126252C1 (es)
SG (1) SG52479A1 (es)
SK (1) SK279554B6 (es)
WO (1) WO1994002141A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324014C2 (de) * 1993-07-17 1995-06-08 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
WO2002015908A1 (fr) * 2000-08-18 2002-02-28 Takeda Chemical Industries, Ltd. Injections
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
EP1713476B1 (en) * 2003-11-05 2010-05-05 Lyka Labs Limited Process for the preparation of benzimidazoles
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007091276A2 (en) * 2006-02-10 2007-08-16 Rajasthan Antibiotic Limited Novel crystal form of omeprazol sodium
CN104288175A (zh) * 2014-09-17 2015-01-21 大生祥(武汉）中医投资管理有限公司 一种新的苯并咪唑类异构体制剂及其制备方法
CN105919953A (zh) * 2016-06-27 2016-09-07 峨眉山通惠制药有限公司 一种注射用奥美拉唑钠组合物及其制作工艺
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
CN112807282A (zh) * 2021-01-13 2021-05-18 海南葫芦娃药业集团股份有限公司 一种奥美拉唑钠冻干粉针剂及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
DE69014141T2 (de) * 1989-02-10 1995-05-24 Takeda Chemical Industries Ltd Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles

Also Published As

Publication number Publication date
SK10095A3 (en) 1995-07-11
NZ254237A (en) 1995-12-21
EP0652751A1 (en) 1995-05-17
KR950702419A (ko) 1995-07-29
FI950379A (fi) 1995-01-27
HU9500245D0 (en) 1995-03-28
DK0652751T3 (da) 1996-11-18
SK279554B6 (sk) 1998-12-02
NO950178L (no) 1995-01-17
SG52479A1 (en) 1998-09-28
HU226778B1 (en) 2009-10-28
HUT71900A (en) 1996-02-28
ATE144421T1 (de) 1996-11-15
CZ284249B6 (cs) 1998-10-14
AU674015B2 (en) 1996-12-05
HK52397A (en) 1997-05-02
WO1994002141A1 (en) 1994-02-03
US5589491A (en) 1996-12-31
EP0652751B1 (en) 1996-10-23
CZ21795A3 (en) 1995-10-18
DE69305642D1 (de) 1996-11-28
CA2140347A1 (en) 1994-02-03
GR3021937T3 (en) 1997-03-31
DE69305642T2 (de) 1997-02-27
FI950379A0 (fi) 1995-01-27
NO304098B1 (no) 1998-10-26
KR100258423B1 (ko) 2000-07-01
AU4583893A (en) 1994-02-14
CA2140347C (en) 2001-03-27
RU2126252C1 (ru) 1999-02-20
NO950178D0 (no) 1995-01-17
FI113338B (fi) 2004-04-15

Similar Documents

Publication Publication Date Title
ES2093445T3 (es) Inyeccion y estuche de inyeccion que contiene omeprazol y sus analogos.
TW342310B (en) Non-systemic external dermal control of parasites
DK0697019T3 (da) Risperidon pamoater
TW200407287A (en) A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it (I)
ATE75936T1 (de) Zusammensetzungen mit verzoegerten wirkstoffabgaben.
DE68919436D1 (de) Stabilisierter, aus Fäden bestehender Vliesstoff.
DK0605469T3 (da) N-phenylpyrazoler som insekticider og acaricider
DE3784501D1 (de) Wasserabweisendes mittel fuer bauwerke.
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
DE3785627D1 (de) Oberflaechenaktives mittel, abgeleitet von hydroxy-substituierten bi- oder tri-carbonsaeuren.
DE69201838D1 (de) Entfernung von gelösten Chelaten aus wässrigen Lösungen.
DE59104044D1 (de) Vorrichtung für den Transport von Substraten.
AR241180A1 (es) Compuesto de benzisoxazol que incluye esteroisomeros del mismo y formulacion herbicida que lo contiene.
DE59203986D1 (de) Vorrichtung für den Transport von Substraten.
CO4650017A1 (es) Artropodicidas de oxazolina
MY106474A (en) Guanidine derivatives.
NO944617D0 (no) Desferrioksamin-B-salter
NO941084L (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
DE3773792D1 (de) Kleine bandkassette.
KR900701262A (ko) 췌장염 등에 대한 치료제
ITRM930408A0 (it) Complessi metalliferi 1:2 asimmetrici di composti azoici. (caso 150-5635)
ES2103222B1 (es) Derivados de tioalquiltiocarbacefalosporina.
AR247655A1 (es) Composicion fungicida que comprende un compuesto derivado de 2-fenil-2-ciano-1-pirazinil (o 1-pirimidinil) alcano c3-c8
SU1496220A1 (ru) Трис(2-гидроксиэтил)аммониевые соли гетерилтиоуксусных кислот, обладающие гиполипидемическим действием
SU1499898A1 (ru) СОЛИ 9-ДИАЛКИЛАМИНОЭТИЛ-2-МЕТИЛ-3-ТЕНОИЛИМИДАЗО[1,2-а]БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ АНТИРАДИОМИМЕТИЧЕСКИМ ДЕЙСТВИЕМ

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652751

Country of ref document: ES